ADMA ADMA BIOLOGICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1368514 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.3%
TTM net income YoY-12.9%
TTM EPS YoY-10.5%
Revenue 3-yr CAGR30.4%
Net income 3-yr CAGR—
Margins
Gross margin68.5%
Operating margin46.5%
Net margin35.1%
FCF margin25.6%
EBITDA margin47.9%
Returns
ROE41.9%
ROA28.0%
ROIC (approx.)39.4%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets40.1%
Debt / equity0.45x
Current ratio6.04x
Interest coverage22.80x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio6.4%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $510.17M | $426.45M | $258.21M | $154.08M | $80.94M |
| Cost of revenue | $217.41M | $206.90M | $169.27M | $118.81M | $79.77M |
| Gross profit | $292.76M | $219.55M | $88.94M | $35.27M | $1.17M |
| R&D expense | $4.76M | $1.81M | $3.30M | $3.61M | $3.65M |
| SG&A expense | $91.58M | $74.12M | $59.02M | $52.46M | $42.90M |
| Operating income | $191.44M | $138.98M | $21.63M | -$39.37M | -$58.37M |
| Interest expense | $7.11M | $13.93M | $25.03M | $19.28M | $13.06M |
| Pretax income | $182.66M | $125.71M | -$28.24M | -$65.90M | — |
| Income tax | $35.73M | -$71.96M | $0 | $0 | $0 |
| Net income | $146.93M | $197.67M | -$28.24M | -$65.90M | -$71.65M |
| EBITDA | $199.44M | $146.68M | $29.23M | -$32.97M | -$53.57M |
| EPS (basic) | 0.62 | 0.85 | -0.13 | -0.33 | -0.51 |
| EPS (diluted) | 0.60 | 0.81 | -0.13 | -0.33 | -0.51 |
| Weighted avg. shares (diluted) | 244.90M | 243.34M | 223.98M | 197.87M | 139.58M |
| Balance sheet | |||||
| Cash & equivalents | $87.63M | $103.15M | $51.35M | $86.52M | $51.09M |
| Receivables | $158.43M | $50.00M | $27.42M | $15.51M | $28.58M |
| Inventory | $206.47M | $170.24M | $172.91M | $163.28M | $124.72M |
| Current assets | $466.51M | $331.41M | $257.01M | $270.40M | $208.73M |
| PP&E, net | $65.06M | $54.71M | $53.84M | $58.26M | $50.94M |
| Goodwill | $3.53M | $3.53M | $3.53M | $3.53M | $3.53M |
| Intangibles | $632,000 | $460,000 | $499,000 | $1.01M | $1.73M |
| Total assets | $624.24M | $488.68M | $329.18M | $348.46M | $276.25M |
| Current liabilities | $69.54M | $55.54M | $49.81M | $39.27M | $30.38M |
| Short-term debt | $2.81M | $0 | — | — | — |
| Long-term debt | $69.33M | $72.34M | $130.59M | $142.83M | $94.87M |
| Total debt | $72.14M | $72.34M | $130.59M | $142.83M | $94.87M |
| Total liabilities | $146.92M | $139.66M | $193.98M | $196.49M | $135.08M |
| Shareholders' equity | $477.32M | $349.02M | $135.21M | $151.97M | $141.17M |
| Net debt | -$15.49M | -$30.81M | $79.24M | $56.31M | $43.78M |
| Shares outstanding | 237.87M | 236.62M | 226.06M | 221.82M | 195.81M |
| Cash flow statement | |||||
| Operating cash flow | $50.40M | $118.67M | $8.80M | -$59.51M | -$112.37M |
| Capital expenditure | $22.57M | $8.23M | $4.77M | $13.91M | $13.51M |
| Free cash flow | $27.82M | $110.45M | $4.03M | -$73.42M | -$125.88M |
| Investing cash flow | -$21.89M | -$8.57M | -$4.98M | -$13.91M | -$13.51M |
| Financing cash flow | -$44.02M | -$58.30M | -$38.99M | $108.85M | $121.05M |
| Depreciation & amortization | $8.00M | $7.70M | $7.60M | $6.40M | $4.80M |
| Stock-based compensation | $20.03M | $13.62M | $6.19M | $5.21M | $3.49M |
| Share buybacks | $31.94M | $0 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.